Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety and efficacy of combining Nivolumab and
low-dose Oxaliplatin with or without Ipilumumab in patients who have had their advanced NSCLC
cancer worsen on or after being treated with certain immunotherapies (drugs that target the
immune system).
Nivolumab (Opdivo®) is approved by the Food and Drug Administration (FDA) for the treatment
of metastatic (the cancer has spread) NSCLC. It is a type of drug called a monoclonal
antibody (a type of protein). Monoclonal antibodies bind to other proteins, such as PD-1
(programmed cell death-1), on immune cells, which allows the immune cells to continue working
against the tumor.
Ipilumumab (Yervoy®) is also a monoclonal antibody, but binds to a protein called CTLA-4
(cytotoxic T-lymphocyte-associated protein 4).
Oxaliplatin is a type of immunogenic chemotherapy, which may increase the body's immune
response to the cancer. Both are approved for treatment of other types of cancers, but not in
patients with NSCLC.